190 related articles for article (PubMed ID: 7841184)
21. Electrostatic parameters of cationic liposomes commonly used for gene delivery as determined by 4-heptadecyl-7-hydroxycoumarin.
Zuidam NJ; Barenholz Y
Biochim Biophys Acta; 1997 Oct; 1329(2):211-22. PubMed ID: 9371413
[TBL] [Abstract][Full Text] [Related]
22. Lipid-based delivery of combinations of antisense oligodeoxynucleotides for the in vitro inhibition of HIV-1 replication.
Lavigne C; Yelle J; Sauvé G; Thierry AG
AAPS PharmSci; 2001; 3(1):E7. PubMed ID: 11741258
[TBL] [Abstract][Full Text] [Related]
23. An antisense oligonucleotide carrier based on amino silica nanoparticles for antisense inhibition of cancer cells.
Peng J; He X; Wang K; Tan W; Li H; Xing X; Wang Y
Nanomedicine; 2006 Jun; 2(2):113-20. PubMed ID: 17292123
[TBL] [Abstract][Full Text] [Related]
24. Biological effects and cellular uptake of c-myc antisense oligonucleotides and their cationic liposome complexes.
Kanamaru T; Takagi T; Takakura Y; Hashida M
J Drug Target; 1998; 5(4):235-46. PubMed ID: 9713974
[TBL] [Abstract][Full Text] [Related]
25. Efficient delivery of intact phosphodiester oligonucleotides by poly-beta-amino esters.
Remaut K; Symens N; Lucas B; Demeester J; De Smedt SC
J Control Release; 2010 May; 144(1):65-74. PubMed ID: 20114066
[TBL] [Abstract][Full Text] [Related]
26. Liposomes as a drug delivery system for antisense oligonucleotides.
Juliano RL; Akhtar S
Antisense Res Dev; 1992; 2(2):165-76. PubMed ID: 1392538
[TBL] [Abstract][Full Text] [Related]
27. Enhanced uptake of antisense oligonucleotides using cationic liposomes and the apoptotic effect of idarubicin in K-562 cell line.
Vellón L; González-Cid M; Karara A; Nebel Mde C; Cuello MT; Larripa I
Leuk Res; 2002 Jul; 26(7):669-76. PubMed ID: 12008085
[TBL] [Abstract][Full Text] [Related]
28. Interaction of oligonucleotides with cationic lipids: the relationship between electrostatics, hydration and state of aggregation.
Meidan VM; Cohen JS; Amariglio N; Hirsch-Lerner D; Barenholz Y
Biochim Biophys Acta; 2000 Apr; 1464(2):251-61. PubMed ID: 10727612
[TBL] [Abstract][Full Text] [Related]
29. Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug.
Garbuzenko OB; Saad M; Betigeri S; Zhang M; Vetcher AA; Soldatenkov VA; Reimer DC; Pozharov VP; Minko T
Pharm Res; 2009 Feb; 26(2):382-94. PubMed ID: 18958402
[TBL] [Abstract][Full Text] [Related]
30. The characterization of cationic fusogenic liposomes mediated antisense oligonucleotides into HeLa cells.
Hu Y; Jin Y; Xia Y
Drug Dev Ind Pharm; 2004 Feb; 30(2):135-41. PubMed ID: 15089047
[TBL] [Abstract][Full Text] [Related]
31. In vitro delivery of antisense oligonucleotides.
Jääskeläinen I; Honkakoski P; Urtti A
Cell Mol Biol Lett; 2002; 7(2):236-7. PubMed ID: 12097930
[No Abstract] [Full Text] [Related]
32. Delivery to cancer cells of antisense L-myc oligonucleotides incorporated in fusogenic, cationic-lipid-reconstituted influenza-virus envelopes (cationic virosomes).
Waelti ER; Glück R
Int J Cancer; 1998 Aug; 77(5):728-33. PubMed ID: 9688306
[TBL] [Abstract][Full Text] [Related]
33. Hyaluronic acid-modified DOTAP/DOPE liposomes for the targeted delivery of anti-telomerase siRNA to CD44-expressing lung cancer cells.
Taetz S; Bochot A; Surace C; Arpicco S; Renoir JM; Schaefer UF; Marsaud V; Kerdine-Roemer S; Lehr CM; Fattal E
Oligonucleotides; 2009 Jun; 19(2):103-16. PubMed ID: 19374532
[TBL] [Abstract][Full Text] [Related]
34. Cationic polyhexylcyanoacrylate nanoparticles as carriers for antisense oligonucleotides.
Zobel HP; Kreuter J; Werner D; Noe CR; Kümel G; Zimmer A
Antisense Nucleic Acid Drug Dev; 1997 Oct; 7(5):483-93. PubMed ID: 9361907
[TBL] [Abstract][Full Text] [Related]
35. Poly(propylacrylic acid) enhances cationic lipid-mediated delivery of antisense oligonucleotides.
Lee LK; Williams CL; Devore D; Roth CM
Biomacromolecules; 2006 May; 7(5):1502-8. PubMed ID: 16677032
[TBL] [Abstract][Full Text] [Related]
36. Folic acid-polylysine carrier improves efficacy of c-myc antisense oligodeoxynucleotides on human melanoma (M14) cells.
Ginobbi P; Geiser TA; Ombres D; Citro G
Anticancer Res; 1997; 17(1A):29-35. PubMed ID: 9066627
[TBL] [Abstract][Full Text] [Related]
37. Novel antisense therapeutics delivery systems: In vitro and in vivo studies of liposomes targeted with anti-CD20 antibody.
Meissner JM; Toporkiewicz M; Czogalla A; Matusewicz L; Kuliczkowski K; Sikorski AF
J Control Release; 2015 Dec; 220(Pt A):515-528. PubMed ID: 26585505
[TBL] [Abstract][Full Text] [Related]
38. Specific inhibition of influenza virus RNA polymerase and nucleoprotein gene expression by liposomally encapsulated antisense phosphorothioate oligonucleotides in MDCK cells.
Abe T; Suzuki S; Hatta T; Takai K; Yokota T; Takaku H
Antivir Chem Chemother; 1998 May; 9(3):253-62. PubMed ID: 9875404
[TBL] [Abstract][Full Text] [Related]
39. A new liposomal formulation for antisense oligodeoxynucleotides with small size, high incorporation efficiency and good stability.
Stuart DD; Allen TM
Biochim Biophys Acta; 2000 Feb; 1463(2):219-29. PubMed ID: 10675501
[TBL] [Abstract][Full Text] [Related]
40. Gene transfection by cationic liposomes: comparison of the transfection efficiency of liposomes prepared from various positively charged lipids.
Zhao DD; Watarai S; Lee JT; Kouchi S; Ohmori H; Yasuda T
Acta Med Okayama; 1997 Jun; 51(3):149-54. PubMed ID: 9227794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
